Abstract
Complex molecular and cellular mechanisms are involved in the pathway of liver fibrosis. Activation and transformation of hepatic stellate cells (HSCs) are considered the two main reasons for the cause and development of liver fibrosis. The peroxisome proliferator-activated receptors (PPARs) belonging to the family of ligand-activated transcription factors play a key role in liver homeostasis, regulating adipogenesis and inhibiting fibrogenesis in HSCs. Normal transcriptional function of PPARs contributes to maintain HSCs in quiescent phase. A reduced expression of PPARs in HSCs greatly induces a progression of liver fibrosis and an increased production of collagen. Here, we discuss role and function of PPARs and we take into consideration molecular factors able to reduce PPARs activity in HSCs. Finally, although further validations are needed, we illustrate novel strategies available from in vitro and animal studies on how some PPARs-agonists have been proved effective as antifibrotic substances in liver disease.
Keywords: Cytokines, genes, HSCs, ligands, liver fibrosis, microcirculation, PPARs, antifbrotic therapy, transcription factors.
Current Medicinal Chemistry
Title:Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
Volume: 20 Issue: 27
Author(s): E. M. Zardi, L. Navarini, G. Sambataro, P. Piccinni, F. M. Sambataro, C. Spina and A. Dobrina
Affiliation:
Keywords: Cytokines, genes, HSCs, ligands, liver fibrosis, microcirculation, PPARs, antifbrotic therapy, transcription factors.
Abstract: Complex molecular and cellular mechanisms are involved in the pathway of liver fibrosis. Activation and transformation of hepatic stellate cells (HSCs) are considered the two main reasons for the cause and development of liver fibrosis. The peroxisome proliferator-activated receptors (PPARs) belonging to the family of ligand-activated transcription factors play a key role in liver homeostasis, regulating adipogenesis and inhibiting fibrogenesis in HSCs. Normal transcriptional function of PPARs contributes to maintain HSCs in quiescent phase. A reduced expression of PPARs in HSCs greatly induces a progression of liver fibrosis and an increased production of collagen. Here, we discuss role and function of PPARs and we take into consideration molecular factors able to reduce PPARs activity in HSCs. Finally, although further validations are needed, we illustrate novel strategies available from in vitro and animal studies on how some PPARs-agonists have been proved effective as antifibrotic substances in liver disease.
Export Options
About this article
Cite this article as:
Zardi M. E., Navarini L., Sambataro G., Piccinni P., Sambataro M. F., Spina C. and Dobrina A., Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment, Current Medicinal Chemistry 2013; 20(27) . https://dx.doi.org/10.2174/09298673113209990136
DOI https://dx.doi.org/10.2174/09298673113209990136 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Statins and Ischaemia Reperfusion Injury: A Molecular Biological Review
Current Vascular Pharmacology Editorial (Thematic Issue: Antiplatelet Treatment in Cardiovascular Disease: New Insights)
Current Pharmaceutical Design Abstracts from Speakers
Cardiovascular & Hematological Disorders-Drug Targets Advanced Echocardiographic Imaging of the Congenitally Malformed Heart
Current Cardiology Reviews Heart Rate Lowering by Inhibition of the Pacemaker Current: A New Therapeutic Perspective in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Host Neuro- Immuno-Endocrine Responses In Periodontal Disease
Current Pharmaceutical Design Effects of Annurca Apple Fruit, a Southern Italy Cultivar, on Lipid Metabolism in Wistar Rats
Current Nutrition & Food Science In Silico Studies in Drug Research Against Neurodegenerative Diseases
Current Neuropharmacology The Roles of Parathyroid Hormone and Calcitonin in Bone Remodeling: Prospects for Novel Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Angiotensin II Receptor Blocker as an Inverse Agonist: A Current Perspective
Current Hypertension Reviews Improvement of Bioactive Potential of Canavalia Beans of Coastal Sand Dunes by Solid-Substrate Fermentation Using Rhizopus oligosporus
Current Nutrition & Food Science Light Directed Gene Transfer by Photochemical Internalisation
Current Gene Therapy Statin Therapy and New-onset Diabetes: Molecular Mechanisms and Clinical Relevance
Current Pharmaceutical Design B-Type Natriuretic Peptide for Diagnosis and Therapy
Recent Patents on Cardiovascular Drug Discovery Short-term RR-Interval Power Spectral Analysis as a New Tool to Stratify the Risk of Sudden Death in Various Cardiovascular Conditions
Vascular Disease Prevention (Discontinued) Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Transplantation of Adipose Tissue-Derived Stem Cells for Treatment of Focal Cerebral Ischemia
Current Neurovascular Research Chemotherapeutic Options for Colorectal Cancer Patients with Cardiovascular Diseases.
Reviews on Recent Clinical Trials The Quality of Life of Thalassemic Patients: The Role of Endocrine Defect Compensation
Endocrine, Metabolic & Immune Disorders - Drug Targets